cas 1118767-15-9|| where to buy tert-butyl 18-[[(2S)-5-[2-[2-[2-[2-[2-[2-(2,5-dioxopyrrolidin-1-yl)oxy-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-[(2-methylpropan-2-yl)oxy]-1,5-dioxopentan-2-yl]amino]-18-oxooctadecanoate

Nombre del producto:tert-butyl 18-[[(2S)-5-[2-[2-[2-[2-[2-[2-(2,5-dioxopyrrolidin-1-yl)oxy-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-[(2-methylpropan-2-yl)oxy]-1,5-dioxopentan-2-yl]amino]-18-oxooctadecanoate

IUPAC Name:tert-butyl 17-{[(2S)-1-(tert-butoxy)-4-({2-[2-({[2-(2-{2-[(2,5-dioxopyrrolidin-1-yl)oxy]-2-oxoethoxy}ethoxy)ethyl]carbamoyl}methoxy)ethoxy]ethyl}carbamoyl)-1-oxobutan-2-yl]carbamoyl}heptadecanoate

: CAS：1118767-15-9; Fórmula molecular：C47H82N4O15; Pureza：95%+

: Número de catálogo：CM590183; Peso molecular：943.19

Unidad de embalaje	Stock disponible	Precio($)
CM590183-100mg	in stock	ƄȀ
CM590183-250mg	in stock	ĽǊǊ
CM590183-1g	in stock	ȎźȀ
CM590183-5g	in stock	ȀŢĽ

Consulta: sales@chemenu.com

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1118767-15-9 regularly via the above email.

Notas adicionales

Verification code*

refresh

Detalles del producto

: Núm. De CAS :1118767-15-9; Fórmula molecular:C47H82N4O15; Punto de fusión:-; Código de sonrisas:CC(C)(C)OC(=O)CCCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)ON1C(=O)CCC1=O)C(=O)OC(C)(C)C; Densidad:

: Número de catálogo:CM590183; Peso molecular:943.19; Punto de ebullición:; Nº Mdl:; Almacenamiento:

Category Infos

: Fatty Acid Modified Side Chains; Fatty acid-modified side chains are small molecule modifiers and are one of the important factors that change the pharmacokinetic behavior of insulin products. Peptide drugs have the problem of short half-life and easy degradation in clinical practice. Introducing fatty acid-modified side chains into peptide drugs can increase the hydrophobicity of the drug and increase the biological half-life, thereby reducing the dosage and frequency of medication.